

(-)-Trans- Δ^9 -Tetrahydrocannabinol-Like Discriminative-Stimulus Effects of Gabapentin in Cannabis Users

Takato Hiranita*

Division of Neurotoxicology, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration (FDA), USA

*Corresponding author: Takato Hiranita, Division of Neurotoxicology, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration (FDA), 3900 NCTR Road, Jefferson, AR 72079-9501, USA, E-mail: takato.hiranita@fda.hhs.gov

Received date: February 01, 2016; Accepted date: February 05, 2016; Published date: February 10, 2016

Copyright: © 2016 Hiranita T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

A recent study by Dr. Joshua Lile and his colleagues demonstrated the capability of gabapentin to produce marijuana-like effects in humans. The finding is unexpected since the primary binding site of gabapentin is not thought to be any of the cannabinoid receptor subtypes. Gabapentin (Neurontin®) (Figure 1) is an FDA-approved medication for the treatment of epilepsy and neuropathic pain and several cases of its off-label use are also known. Several case reports have indicated gabapentin misuse/abuse [1-4] but the *in vivo* pharmacology and abuse potential of gabapentin have not yet been directly characterized. Thus, there is a clear need to characterize the *in vivo* pharmacology of gabapentin including its abuse potential.

In contrast to the *in vivo* assessment, the *in vitro* pharmacology of gabapentin has relatively been characterized. Gabapentin is a structural analogue of the inhibitory neurotransmitter γ -aminobutyric acid (GABA) and 3 branched-chain γ -amino acids (L-isoleucine, L-leucine, and L-methionine) (Figure 1). Despite its structural similarity to GABA and these branched-chain γ -amino acids, several studies using radio ligand binding assays have reported low, if any, affinity of gabapentin (3-cyclohexyl-GABA) for GABA receptor subtypes (no inhibition at up to 1,000,000 nM) [5,6] and low, if any, potency to inhibit the uptake of [³H]-GABA (K_i value: 50,000 nM) [7] or [³H]-leucine (K_i value: 30,000 nM) [8].




Figure 1: Chemical structures of gabapentin, γ -aminobutyric acid (GABA), pregabalin and three branched-chain γ -amino acids.

In marked contrast to GABA receptor subtypes, several *in vivo* studies on [³H] gabapentin-binding sites have found a 26,300-fold higher affinity of gabapentin for auxiliary $\alpha_2\delta$ ($\alpha_2\delta$ -1 and $\alpha_2\delta$ -2) subunits on voltage-dependent calcium (Ca²⁺) channels (VDCCs) [9,10] in cerebral cortices of rats [5] and mice [11] (K_d values: 38 and

23 nM, respectively). Consistent with their structural similarity to gabapentin, several compounds (Figure 1) have been shown to be high-affinity ligands at the [³H] gabapentin-binding site. These include pregabalin [12] and the three branched-chain γ -amino acids (L-isoleucine, L-leucine, and L-methionine) [5] (IC₅₀ values: 50-80 nM). GABA, however, has at least a 7,630-fold lower affinity for the [³H] gabapentin binding site *in vivo* (IC₅₀ value: 610,000 nM) [5]. Based on the results from these studies using [³H] gabapentin, it is not surprising that gabapentin can influence a VDCC-mediated effect [13].

Drug discrimination procedures have high human predictive validity with respect to the subjective effects of various test articles across pharmacological classes and have served as the gold standards for characterizing drug pharmacology *in vivo* because of their high pharmacological specificity [14-17]. Assessment of the capacity of gabapentin to induce a discriminative-stimulus (DS) in drug naive subjects has not been reported. Interestingly, several L-VDCC blockers (nifedipine and verapamil) by themselves have been demonstrated to condition place preference in drug naive rats using a place-conditioning procedure [18]. Considering the potential of gabapentin to serve as a functional L-VDCC antagonist [13,19,20], gabapentin alone at an appropriate dose and treatment time may exert an *in vivo* action indicative of its abuse potential.

Several studies using drug discrimination procedures have assessed the capacity of gabapentin or pregabalin to substitute for various psychoactive compounds from different pharmacological classes [21-26]. Among them is a double-blind, placebo-controlled, clinical study that found gabapentin capable of full substitution for the cannabinoid CB_{1/2} receptor (CB_{1/2}R) partial agonist (-)-trans- Δ^9 -tetrahydrocannabinol (Δ^9 -THC) in Cannabis users trained to discriminate ingestion of Δ^9 -THC from ingestion of placebo [26]. However, this clinical result is inconsistent with preclinical findings that indicate a lack of cannabinoid-like DS effects for gabapentin in rats trained to discriminate another cannabinoid CB_{1/2}R partial agonist, BAY 59-3074 [23]. There is currently no literature on the assessment of the binding affinity of gabapentin and other high-affinity ligands at the [³H] gabapentin-binding site for any cannabinoid receptor subtypes or endocannabinoid [e.g. anandamide and 2-arachidonoylglycerol (2-AG)] uptake enzymes. Δ^9 -THC [27,28] and BAY 59-3074 [29] have been reported to have substantial, high affinity for cannabinoid CB₁ and CB₂ receptor subtypes (K_i values: 15.3-55.4 nM). Δ^9 -THC also is known to exert potent action that is mediated through non-CB_{1/2}R, cannabinoid G protein-coupled receptor 55 (GPR55) [30,31] that is expressed in human [32] and rat [33,34] brains while it is unknown whether BAY 59-3074 has actions at the cannabinoid GPR55. Importantly, cannabinoid GPR55 has been found to increase intracellular Ca²⁺ levels [31] and a recent *in vitro* study using a Bioluminescence Resonance Energy Transfer (BRET) assay

demonstrated that cannabinoid GPR55 can form a heteromer with cannabinoid CB1R [34] in the rat striatum. In addition, another study identified a heteromer consisting of cannabinoid CB₂R and GPR55 [35]. Considering the well-characterized effect of cannabinoid CB1R agonists as L-VDCC blockers [36-42] and the potential of gabapentin to serve as a functional L-VDCC blocker [13,19,20], the full Δ^9 -THC-like DS effects of gabapentin in Cannabis users [26] might result from a blocking action of gabapentin and Δ^9 -THC at L-VDCCs.

In summary, it does appear pharmacologically important comprehensively to assess the L-VDCC-blocker- and cannabinoid-like DS effects of gabapentin and pregabalin for regulatory purposes. Further it may be important to assess whether gabapentin and pregabalin can enhance reinforcing and toxic effects of Δ^9 -THC and cannabinoid products. Given the clinical use of L-VDCC blockers against hypertension, such studies would also have significant impact on their safer use.

Acknowledgement

The present work was supported by the Division of Neurotoxicology/NCTR/U.S. FDA. The information in the present article is not a formal dissemination of information by the FDA and does not represent agency position or policy. The author thanks Dr. Merle G. Paule for comments on the preparation of the manuscript.

References:

1. Satish R, Kandasamy A, Jayarajan D, Benegal V (2015) Gabapentin dependence in a patient with opioid dependence syndrome. J Neuropsychiatry Clin Neurosci 27: e64.
2. Häkkinen M, Vuori E, Kalso E, Gergov M, Ojanperä I (2014) Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int 241: 1-6.
3. Schifano F (2014) Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs 28: 491-496.
4. Howland RH (2014) Gabapentin: can it be misused? J Psychosoc Nurs Ment Health Serv 52: 12-25.
5. Suman-Chauhan N, Webdale L, Hill DR, Woodruff GN (1993) Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies. Eur J Pharmacol 244: 293-301.
6. Lanneau C, Green A, Hirst WD, Wise A, Brown JT, et al. (2001) Gabapentin is not a GABAB receptor agonist. Neuropharmacology 41: 965-975.
7. Eckstein-Ludwig U, Fei J, Schwarz W (1999) Inhibition of uptake, steady-state currents, and transient charge movements generated by the neuronal GABA transporter by various anticonvulsant drugs. Br J Pharmacol 128: 92-102.
8. Belliotti TR, Capiris T, Ekhatov IV, Kinsora JJ, Field MJ, et al. (2005) Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein. J Med Chem 48: 2294-2307.
9. Marais E, Klugbauer N, Hofmann F (2001) Calcium channel alpha(2)delta subunits-structure and Gabapentin binding. Mol Pharmacol 59: 1243-1248.
10. Field MJ, Cox PJ, Stott E, Melrose H, Offord J, et al. (2006) Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A 103: 17537-17542.
11. Bian F, Li Z, Offord J, Davis MD, McCormick J, et al. (2006) Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an *ex vivo* autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res 1075: 68-80.
12. Taylor BK, Peterson MA, Basbaum AI (1997) Early nociceptive events influence the temporal profile, but not the magnitude, of the tonic response to subcutaneous formalin: effects with remifentanyl. J Pharmacol Exp Ther 280: 876-883.
13. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, et al. (2002) Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42: 229-236.
14. Holtzman SG (1985) Drug discrimination studies. Drug Alcohol Depend 14: 263-282.
15. Schuster CR, Johanson CE (1988) Relationship between the discriminative stimulus properties and subjective effects of drugs. Psychopharmacol Ser 4: 161-175.
16. Hiranita T, Soto PL, Tanda G, Katz JL (2011) Lack of Cocaine-Like Discriminative-Stimulus Effects of σ Receptor Agonists in Rats. Behav Pharmacol 22:525-530.
17. Kohut SJ, Hiranita T, Hong SK, Ebbs AL, Tronci V, et al. (2014) Preference for distinct functional conformations of the dopamine transporter alters the relationship between subjective effects of cocaine and stimulation of mesolimbic dopamine. Biol Psychiatry 76: 802-809.
18. Biala G, Langwinski R (1996) Effects of calcium channel antagonists on the reinforcing properties of morphine, ethanol and cocaine as measured by place conditioning. J Physiol Pharmacol 47: 497-502.
19. Stefani A, Spadoni F, Bernardi G (1998) Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 37: 83-91.
20. Sutton KG, Martin DJ, Pinnock RD, Lee K, Scott RH (2002) Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. Br J Pharmacol 135: 257-265.
21. Besheer J, Frisbee S, Randall PA, Jaramillo AA, Masciello M (2016) Gabapentin potentiates sensitivity to the interoceptive effects of alcohol and increases alcohol self-administration in rats. Neuropharmacology 101: 216-224.
22. McDonald LM, Sheppard WF, Staveley SM, Sohal B, Tattersall FD, et al. (2008) Discriminative stimulus effects of tiagabine and related GABAergic drugs in rats. Psychopharmacology (Berl) 197: 591-600.
23. De Vry J, Jentsch KR (2004) Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat. Eur J Pharmacol 505: 127-133.
24. Filip M, Frankowska M, Zaniewska M, Gołda A, Przegaliński E, et al. (2007) Diverse effects of GABA-mimetic drugs on cocaine-evoked self-administration and discriminative stimulus effects in rats. Psychopharmacology (Berl) 192: 17-26.
25. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, et al. (1997) Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 121: 1513-1522.
26. Lile JA, Wesley MJ, Kelly TH, Hays LR (2015) Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol. Behav Pharmacol.
27. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, et al. (2011) Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 6: e21917.
28. Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989-999.
29. De Vry J, Denzer D, Reissmueller E, Eijckenboom M, Heil M, et al. (2004) 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butananesulfo nate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects. J Pharmacol Exp Ther 310: 620-632.
30. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, et al. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101.
31. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, et al. (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105: 2699-2704.

32. Sawzdargo M, Nguyen T, Lee DK, Lynch KR, Cheng R, et al. (1999) Identification and cloning of three novel human G protein-coupled receptor genes GPR52, GPR53 and GPR55: GPR55 is extensively expressed in human brain. *Brain Res Mol Brain Res* 64: 193-198.
33. Coria SM, Roura-Martínez D, Ucha M, Assis MA, Miguéns M, et al. (2014) Strain differences in the expression of endocannabinoid genes and in cannabinoid receptor binding in the brain of Lewis and Fischer 344 rats. *Prog Neuropsychopharmacol Biol Psychiatry* 53: 15-22.
34. Martínez-Pinilla E, Reyes-Resina I, Oñatibia-Astibia A, Zamarbide M, Ricobaraza A, et al. (2014) CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum. *Exp Neurol* 261: 44-52.
35. Moreno E, Andradas C, Medrano M, Caffarel MM, Pérez-Gómez E, et al. (2014) Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. *J Biol Chem* 289: 21960-21972.
36. Ross HR, Napier I, Connor M (2008) Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. *J Biol Chem* 283: 16124-16134.
37. Muntoni AL, Pillolla G, Melis M, Perra S, Gessa GL, et al. (2006) Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons. *Eur J Neurosci* 23: 2385-2394.
38. Rao GK, Kaminski NE (2006) Kaminski, Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship. *J Pharmacol Exp Ther* 317: 820-829.
39. Oz M, Tchugunova Y, Dinc M (2004) Differential effects of endogenous and synthetic cannabinoids on voltage-dependent calcium fluxes in rabbit T-tubule membranes: comparison with fatty acids. *Eur J Pharmacol* 502: 47-58.
40. Begg M, Mo FM, Offertaler L, Bátakai S, Pacher P, et al. (2003) G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca^{2+} -dependent K^+ current. *J Biol Chem* 278: 46188-46194.
41. Nadler V, Biegon A, Beit-Yannai E, Adamchik J, Shohami E (1995) ^{45}Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211. *Brain research* 685: 1-11.
42. Lozovaya N, Min R, Tsintsadze V, Burnashev N (2009) Dual modulation of CNS voltage-gated calcium channels by cannabinoids: Focus on CB1 receptor-independent effects. *Cell Calcium* 46: 154-162.